Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
13.06
-0.20 (-1.51%)
At close: Sep 17, 2025, 4:00 PM EDT
13.44
+0.38 (2.91%)
After-hours: Sep 17, 2025, 6:25 PM EDT
Denali Therapeutics Employees
Denali Therapeutics had 422 employees as of December 31, 2024. The number of employees decreased by 23 or -5.17% compared to the previous year.
Employees
422
Change (1Y)
-23
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,135,152
Market Cap
1.91B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 422 | -23 | -5.17% |
| Dec 31, 2023 | 445 | 18 | 4.22% |
| Dec 31, 2022 | 427 | 47 | 12.37% |
| Dec 31, 2021 | 380 | 89 | 30.58% |
| Dec 31, 2020 | 291 | 30 | 11.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DNLI News
- 8 days ago - Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - The Best Small-Cap Stocks to Buy Now - Kiplinger
- 5 weeks ago - Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) - GlobeNewsWire
- 4 months ago - Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome - GlobeNewsWire
- 6 months ago - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewsWire
- 6 months ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 6 months ago - Denali Therapeutics: Vast Pipeline, First Approval Up Ahead - Seeking Alpha